


Chapter 6

First Episode Psychosis and Cognition

Gilberto Sousa Alves

 <https://orcid.org/0000-0002-0463-6183>
Federal University of Rio de Janeiro, Brazil

Romulo Kunrath Pinto Silva

Nina Rodrigues Hospital, Brazil

Marielia Barbosa Freitas Leal

Federal University of Ceará, Brazil

Bianca de Melo Ferro

Federal University of Maranhao, Brazil

Leandro de Oliveira Trovão

Nina Rodrigues Hospital, Brazil

ABSTRACT

The experience of the psychosis can open a critical window into primary psychiatric conditions, particularly schizophrenia or bipolar disorder. More recently, the role of environment in early adolescence or late childhood, including psychological abuse or physical violence, has been associated with a greater likelihood of developing psychosis years later. Evidence has also shown, even in symptomatic remission, the occurrence of cognitive symptoms, particularly in complex attention, executive functioning, episodic memory, and verbal and procedural IQ. The current chapter discusses the epidemiology of first episode psychosis, neurobiological characteristics, and main risk factors, including early exposure to the trauma situation and early interventions.

DOI: 10.4018/979-8-3693-0851-6.ch006

INTRODUCTION

Psychosis can be conceptualized as a combination of symptoms resulting in a disconnection of reality and a severe impact on an individual's functionality and quality of life. The experience of the psychotic phenomenon can open a critical window into primary psychiatric conditions, particularly schizophrenia, schizoaffective disorder, or bipolar disorder. The use of psychoactive substances, such as marijuana, cocaine, and synthetic drugs (LSD, MDMA), as well as a variety of infectious, autoimmune, and vascular medical conditions, among others, may be related to psychotic episodes as etiological or predisposing factors. More recently, the role of environmental experiences in early adolescence or late childhood, including psychological abuse or physical violence, has been associated with a greater likelihood of developing psychosis years later. The emergence of first-episode psychosis (FEP) varies widely, usually occurring at the end of adolescence and the beginning of adult life. The operational concept of first-episode psychosis usually encompasses a wide range of categories: first treatment contact, duration of antipsychotic medication, and duration of psychotic episode (Breitborde et al., 2009). A determining factor for progression to severe symptoms is the intensity of psychotic symptoms, such as delusions and hallucinations. In addition to behavioral symptoms, psychotic conditions are often accompanied by negative symptoms (reduced emotional expression, sociability, avolition, and anhedonia). Furthermore, evidence has shown, even in individuals with symptomatic remission, the occurrence of cognitive symptoms, particularly in complex attention, executive functioning, episodic memory, and verbal and procedural IQ, among others. The current chapter discusses factors such as the epidemiology of FEP, neurobiological characteristics, and main risk factors, including early exposure to the trauma situation and early interventions.

1. Prevalence of Psychosis in Adolescents and Early Adulthood

Psychosis, from a broader perspective, affects approximately 3% of the global population, with schizophrenia representing its most severe and prevalent form, affecting approximately 1% of individuals throughout their lives (McCleery & Nuechterlein, 2019). Adolescence represents a significant sociocultural phenomenon associated with psychological reshaping regarding how individuals perceive themselves and the world. During this period, certain aspects of personality, such as self-concept and self-esteem, develop, influencing preferences and the quest for acceptance within peer groups (Lepre & De Oliveira, 2022).

The neurobiology of FEP may involve the disruption of crucial brain functions, notably affecting fronto-striatal and temporal circuits. Furthermore, its clinical

18 more pages are available in the full version of this document, which may be purchased using the "Add to Cart" button on the publisher's webpage: www.igi-global.com/chapter/first-episode-psychosis-and-cognition/342885

Related Content

Alzheimer's and Parkinson's Disease Novel Therapeutic Target: The Mitochondrial Pyruvate Carrier - Ligand Docking to Screen Natural Compounds Related to Classic Inhibitors

Allen K. Bourdon, Greg Villareal, George Perry and Clyde F. Phelix (2021). *Research Anthology on Diagnosing and Treating Neurocognitive Disorders* (pp. 411-426). www.irma-international.org/chapter/alzheimers-and-parkinsons-disease-novel-therapeutic-target/261645

Executive Functions as an Interface in Language Development: Intentional Verbal Resources in Early Stages

Milagros Fernández-Pérez and Iván Enríquez Martínez (2022). *Handbook of Research on Neurocognitive Development of Executive Functions and Implications for Intervention* (pp. 126-154). www.irma-international.org/chapter/executive-functions-as-an-interface-in-language-development/300938

Impact of Hydrocarbon Exposure on the Risk of Parkinson's Disease

Soraia El Baz, Rania Lotfi, Nouredine Mezrioui, Abdelmohcine Aimrane, Ahmed Draoui, Bilal El-Mansoury, Mohamed Echchakery, Ouafae El Hamiani, Hanane Moummou and Lamia Daghor (2023). *Experimental and Clinical Evidence of the Neuropathology of Parkinson's Disease* (pp. 196-218). www.irma-international.org/chapter/impact-of-hydrocarbon-exposure-on-the-risk-of-parkinsons-disease/327975

The Psychoneuroimmunological Perspective of the Coping Mechanism

Shaorn Sucharitha Gold Nemalladinne (2025). *Research Methodologies and Practical Applications in Psychoneuroimmunology* (pp. 557-578). www.irma-international.org/chapter/the-psychoneuroimmunological-perspective-of-the-coping-mechanism/372784

The Role of Neuroscience in Pain Management and Anesthesia

Grandhi Sri Kavya, Pamidimarri Datta Sai and Soumya Saswati Panigrahi (2025).

Advancing Medical Research Through Neuroscience (pp. 489-524).

www.irma-international.org/chapter/the-role-of-neuroscience-in-pain-management-and-anesthesia/371147